Acceptability of Cancer Chemoprevention Trials: Impact of the Design

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2008 Sep 5

PMID 18769562

Citations 3

Authors

Anne-Sophie Maisonneuve

Laetitia Huiart

Laetitia Rabayrol

Doug Horsman

Remi Didelot

Hagay Sobol

Francois Eisinger

Affiliations

Soon will be listed here.

Abstract

Background: Chemoprevention could significantly reduce cancer burden. Assessment of efficacy and risk/benefit balance is at best achieved through randomized clinical trials.

Methods: At a periodic health examination center 1463 adults were asked to complete a questionnaire about their willingness to be involved in different kinds of preventive clinical trials.

Results: Among the 851 respondents (58.2%), 228 (26.8%) agreed to participate in a hypothetical chemoprevention trial aimed at reducing the incidence of lung cancer and 116 (29.3%) of 396 women agreed to a breast cancer chemoprevention trial. Randomization would not restrain participation (acceptability rate: 87.7% for lung cancer and 93.0% for breast cancer). In these volunteers, short-term trials (1 year) reached a high level of acceptability: 71.5% and 73.7% for lung and breast cancer prevention respectively. In contrast long-term trials (5 years or more) were far less acceptable: 9.2% for lung cancer (OR=7.7 CI(95%) 4.4-14.0) and 10.5 % for breast cancer (OR=6.9 CI(95%) 3.2-15.8). For lung cancer prevention, the route of administration impacts on acceptability with higher rate 53.1% for a pill vs. 7.9% for a spray (OR=6.7 CI(95%) 3.6-12.9).

Conclusion: Overall healthy individuals are not keen to be involved in chemo-preventive trials, the design of which could however increase the acceptability rate.

Citing Articles

Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.

Meiser B, Wong W, Peate M, Julian-Reynier C, Kirk J, Mitchell G Hered Cancer Clin Pract. 2017; 15:14.

PMID: 28943990 PMC: 5607482. DOI: 10.1186/s13053-017-0075-8.

Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences.

Finckh A, Escher M, Liang M, Bansback N Curr Rheumatol Rep. 2016; 18(8):51.

PMID: 27402108 DOI: 10.1007/s11926-016-0598-4.

Reasons for and against participation in studies of medicinal therapies for women with breast cancer: a debate.

Luschin G, Habersack M, Gerlich I BMC Med Res Methodol. 2012; 12:25.

PMID: 22405127 PMC: 3329416. DOI: 10.1186/1471-2288-12-25.

References

Greenwald P, McDonald S, Anderson D . An evidence-based approach to cancer prevention clinical trials. Eur J Cancer Prev. 2003; 11 Suppl 2:S43-7. View

Port E, Montgomery L, Heerdt A, Borgen P . Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001; 8(7):580-5. DOI: 10.1007/s10434-001-0580-9. View

Shea S . Hypertension control, 1994. Am J Public Health. 1994; 84(11):1725-7. PMC: 1615212. DOI: 10.2105/ajph.84.11.1725. View

Bober S, Hoke L, Duda R, Regan M, Tung N . Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol. 2004; 22(24):4951-7. DOI: 10.1200/JCO.2004.05.192. View

Singer S, Gaba D, Geppert J, Sinaiko A, Howard S, Park K . The culture of safety: results of an organization-wide survey in 15 California hospitals. Qual Saf Health Care. 2003; 12(2):112-8. PMC: 1743680. DOI: 10.1136/qhc.12.2.112. View

Eisinger F, Giordanella J, Brigand A, Didelot R, Jacques D, Schenowitz G . Cancer prone persons. A randomized screening trial based on colonoscopy: background, design and recruitment. Fam Cancer. 2003; 1(3-4):175-9. DOI: 10.1023/a:1021177417531. View

Evans D, Lalloo F, Shenton A, Boggis C, Howell A . Uptake of screening and prevention in women at very high risk of breast cancer. Lancet. 2001; 358(9285):889-90. DOI: 10.1016/S0140-6736(01)06039-1. View

Freedman A, Graubard B, Rao S, McCaskill-Stevens W, Ballard-Barbash R, Gail M . Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003; 95(7):526-32. DOI: 10.1093/jnci/95.7.526. View

Sun S, Hail Jr N, Lotan R . Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst. 2004; 96(9):662-72. DOI: 10.1093/jnci/djh123. View

10.

Eisinger F, Geller G, Burke W, Holtzman N . Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer. Lancet. 1999; 353(9156):919-20. DOI: 10.1016/s0140-6736(98)07516-3. View

11.

Herberman R, Pearce H, Lippman S, Pyenson B, Alberts D . Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need. Cancer Res. 2006; 66(24):11540-9. DOI: 10.1158/0008-5472.CAN-06-4122. View

12.

Goldie S, Kohli M, Grima D, Weinstein M, Wright T, Bosch F . Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96(8):604-15. DOI: 10.1093/jnci/djh104. View

13.

Bastian L, Lipkus I, Kuchibhatla M, Weng H, Halabi S, Ryan P . Women's interest in chemoprevention for breast cancer. Arch Intern Med. 2001; 161(13):1639-44. DOI: 10.1001/archinte.161.13.1639. View

14.

Rondanina G, Puntoni M, Severi G, Varricchio C, Zunino A, Feroce I . Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol. 2008; 26(9):1537-43. DOI: 10.1200/JCO.2007.13.6739. View

15.

Bacchetti P . Peer review of statistics in medical research: the other problem. BMJ. 2002; 324(7348):1271-3. PMC: 1123222. DOI: 10.1136/bmj.324.7348.1271. View

16.

Kerr C, Robinson E, Stevens A, Braunholtz D, Edwards S, Lilford R . Randomisation in trials: do potential trial participants understand it and find it acceptable?. J Med Ethics. 2004; 30(1):80-4. PMC: 1757143. DOI: 10.1136/jme.2002.001123. View

17.

Vourlekis J, Szabo E . Predicting success in cancer prevention trials. J Natl Cancer Inst. 2003; 95(3):178-9. DOI: 10.1093/jnci/95.3.178. View

18.

Motl R, McAuley E, DiStefano C . Is social desirability associated with self-reported physical activity?. Prev Med. 2005; 40(6):735-9. DOI: 10.1016/j.ypmed.2004.09.016. View

19.

Murphy M, Wei L, Watson A, MacDonald T . 'Real-life' reduction in cholesterol with statins, 1993 to 2002. Br J Clin Pharmacol. 2008; 65(4):587-92. PMC: 2291374. DOI: 10.1111/j.1365-2125.2007.03066.x. View

20.

Extermann M, Albrand G, Chen H, Zanetta S, Schonwetter R, Zulian G . Are older French patients as willing as older American patients to undertake chemotherapy?. J Clin Oncol. 2003; 21(17):3214-9. DOI: 10.1200/JCO.2003.08.091. View